Veru (VERU) Net Cash Flow (2010 - 2026)
Veru (VERU) posted quarterly Net Cash Flow of -$5.4 million for Q1 2026, up 18.99% year-over-year from -$4.5 million in Q1 2025, and down 131.25% quarter-over-quarter from $17.2 million in Q4 2025.
Veru (VERU) Net Cash Flow (2010 - 2026) Analysis & Trends
Veru (VERU) has reported Net Cash Flow for 17 consecutive years, with -$5.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow rose 18.99% year-over-year to -$5.4 million; the TTM figure through Mar 2026 stood at $7.6 million (up 151.72% YoY), while the FY2025 annual figure was -$9.1 million, down 159.44% from the prior year.
- Net Cash Flow eased to -$5.4 million in Q1 2026 per VERU's latest filing, from $17.2 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $31.0 million in Q4 2023 and bottomed at -$33.3 million in Q4 2022.
- Historically, Net Cash Flow has averaged -$5.2 million across 5 years, with a median of -$5.6 million in 2024.
- Annual changes were most pronounced in 2022 — Net Cash Flow tumbled 2456.39% — and 2025, when it soared 895.9%.
- Veru's Net Cash Flow stood at -$33.3 million in 2022, then soared by 193.06% to $31.0 million in 2023, then sank by 94.43% to $1.7 million in 2024, then jumped by 895.9% to $17.2 million in 2025, then sank by 131.25% to -$5.4 million in 2026.
- Business Quant data shows VERU's Net Cash Flow at -$5.4 million in Q1 2026, $17.2 million in Q4 2025, and $827496.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Veru | 60.85 Mn | 35.06 Mn | - | -3.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.75 Mn |
| Jun 30, 2026 | -3.75 Mn |
| Mar 31, 2026 | -5.36 Mn |
| Mar 31, 2026 | -5.36 Mn |
| Dec 31, 2025 | 17.17 Mn |
| Dec 31, 2025 | 17.17 Mn |
| Sep 30, 2025 | 827,496.00 |
| Sep 30, 2025 | 827,496.00 |
| Jun 30, 2025 | -5.01 Mn |
| Jun 30, 2025 | -5.01 Mn |
| Mar 31, 2025 | -6.62 Mn |
| Mar 31, 2025 | -6.62 Mn |
| Dec 31, 2024 | 1.72 Mn |
| Dec 31, 2024 | 1.72 Mn |
| Sep 30, 2024 | -4.25 Mn |
| Sep 30, 2024 | -4.25 Mn |
| Jun 30, 2024 | -5.59 Mn |
| Jun 30, 2024 | -5.59 Mn |
| Mar 31, 2024 | -5.84 Mn |
| Mar 31, 2024 | -5.84 Mn |